El infarto de miocardio en el diabético: implicaciones clínicas, pronósticas y terapéuticas en la era trombolítico-intervencionista

Budget Impact of Improved Diabetes Management by Utilization of Glucose Meters With a Color-Range Indicator—Comparison of Five European Healthcare Systems

“…These costs involve direct costs for acute MI, direct costs for follow-up (first year), and direct costs for successfully treated MI. Latest available data for these diabetes-related costs were retrieved from the following references: France, [21][22][23][24] Germany, 25,26 Italy, [27][28][29] Spain, [30][31][32][33][34][35][36] and the United Kingdom [37][38][39][40][41][42][43] (summarized in Table 1).…”

“…National and international publications provided the current values of expenditures for both fatal and nonfatal MI events. 20,22,23,28,31,32,38,39,42,43 According to fatal MI events in the diabetic population, fatal MI events were estimated for insulin-treated patients. Costs for fatal and nonfatal MI events were calculated as acute treatment costs and successfully treated (acute treatment costs summed with the first-year follow-up costs).…”

Pan-European Economic Analysis to Identify Cost Savings for the Health Care Systems as a Result of Integrating Glucose Monitoring Based Telemedical Approaches Into Diabetes Management

“…Expenditures were estimated for both fatal and nonfatal MI events based on current numbers from various national and international publications. [28][29][30][31][32][33][34][35] Percentage of fatal events were extracted from overall MI events in the diabetes population. Nonfatal MI events were calculated for acute and nonacute MI events for successfully treated patients within one year.…”